Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...